Modality
ASO
MOA
Menini
Target
CD47
Pathway
Notch
CMLMeso
Development Pipeline
Preclinical
~Dec 2009
→ ~Mar 2011
Phase 1
~Jun 2011
→ ~Sep 2012
Phase 2
~Dec 2012
→ ~Mar 2014
Phase 3
~Jun 2014
→ ~Sep 2015
NDA/BLA
~Dec 2015
→ ~Mar 2017
Approved
Jun 2017
→ Sep 2031
ApprovedCurrent
NCT03844168
759 pts·Meso
2017-06→2025-03·Active
NCT05259219
175 pts·CML
2019-12→2031-09·Completed
NCT07354042
1,565 pts·CML
2023-01→2026-04·Not yet recruiting
+1 more trial
4,168 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-03-151.0y agoPh3 Readout· Meso
2026-04-033d awayPh3 Readout· CML
2031-09-185.5y awayPh3 Readout· CML
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Active
Approved
Not yet…
Approved
Complet…
Approved
Not yet…
Catalysts
Ph3 Readout
2025-03-15 · 1.0y ago
Meso
Ph3 Readout
2026-04-03 · 3d away
CML
Ph3 Readout
2031-09-18 · 5.5y away
CML
ActiveCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03844168 | Approved | Meso | Active | 759 | UPCR |
| NCT05259219 | Approved | CML | Completed | 175 | ORR |
| NCT07354042 | Approved | CML | Not yet recr... | 1565 | CR |
| NCT06524237 | Approved | Meso | Not yet recr... | 1669 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 | |
| INC-2432 | Incyte | Phase 2 | CD47 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 |